News – Page 12 – Alligator Bioscience

2022-11-10

Data presented on mitazalimab and ATOR-1017 in Two Poster Presentations at SITC Annual Meeting 2022 – November 8-12, 2022

Mitazalimab data show the CD40 agonist induces strong immune responses in patients with advanced stage solid tumors and further strengthens ...

2022-11-09

ALG.APV-527 Demonstrates Favorable Preclinical Efficacy and Safety Compared to a First Generation 4-1BB Antibody ALG.APV-527 Rapidly Progres ...

2022-11-08

Study to evaluate AC101 (HLX22) in combination with anti-PD-1 antibody serplulimab, trastuzumab and chemotherapy in gastric cancer Phase 2 c ...

2022-11-02

Article shows CD40 x TAA bispecific antibodies can induce enhanced T cell cross-priming superior to monospecific CD40 antibodies using in vi ...

2022-11-01

Lund, Sweden, November 1, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives wi ...

2022-10-24

Lund, Sweden, October 24, 2022– Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparation ...

2022-10-20

Patient enrolment for OPTIMIZE-1 Phase 2 study ahead of schedule with top-line data now brought forward to Q1 2024 and interim data on track ...

2022-10-17

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) will host a conference call (in English) for investors, analysts and media ...

2022-10-10

Lund, Sweden, October 10, 2022 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announced that Mattias Levin, PhD, Sr Team Ma ...